

B2  
Claim 5. The method of claim 1, wherein said growth-factor receptor is epidermal  
growth-factor receptor (EGFR) (EGFR).

RECEIVED

DEC 15 2004

Sub D5  
Claim 17. The method of any one of the previous claims for the prevention or  
treatment of disorders associated with or accompanied by a disturbed [, e.g.  
pathologically enhanced] growth factor receptor activation.

Sub D5  
Claim 19, line 2, please delete "pharmaceutically acceptable composition" and  
substitute --pharmaceutical composition-- therefore.

Please add new claim 21 as follows:

Sub D5  
Claim 21. The method of claim 17 for the prevention or treatment of disorders  
associated with or accompanied by a [disturbed, e.g.] pathologically enhanced growth  
factor receptor activation.

## REMARKS

Claims 1-20 are currently pending. Claims 1-20 are rejected. Claims 2 and 3 are  
objected to. Claim 2 is canceled and claims 1, 5, 17 and 19 amended. New claim 21 is  
added. Support for new claim 21 can be found throughout the application as filed  
including original claim 17. No new matter has been added. Applicants respectfully  
request reconsideration and withdrawal of all rejections.